Pharmacogenomics defines how genes can influence response to drugs. Pharmacopeia is expected to treat a wide range of health problems in the near future, including cardiovascular disease, Alzheimer's disease, cancer, HIV/AIDS and asthma. A growing biotechnology industry boosts the market growth. According to the Organization for Economic Co-operation and Development (OECD) in 2017, biotechnology R&D in the corporate sector accounted for 11.3% each and 9.4% of total corporate R&D in the United States and France in 2014. Also, according to BIOCOM AG in 2016, the total turnover of biotechnology companies headquartered in Germany was $3.7 billion. In addition, rising healthcare spending and growing interest in personalized medicine will drive the market growth. However, lack of awareness and consistency in pharmacogenomics products will restrain the market growth during the forecast period.